Ionis Pharmaceuticals competitorsClear all

Ionis Pharmaceuticals's top competitors include Intellia Therapeutics, Ultragenyx Pharmaceutical, Bluebird Bio, Reata Pharmaceuticals and Arrowhead Pharmaceuticals.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
Ionis Pharmaceuticals
Ionis Pharmaceuticals
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
Intellia Therapeutics
Intellia Therapeutics
Intellia is developing therapeutic products to help people with genetic diseases.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Bluebird Bio
Bluebird Bio
Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer.
Reata Pharmaceuticals
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
Founding Date
Founding Date
1989
Founding Date
2014
Founding Date
2010
Founding Date
1992
Founding Date
2002
Founding Date
2004
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Carlsbad, US HQ
Locations
Cambridge, US HQ
Locations
Novato, US HQ
Locations
Cambridge, US HQ
Paris, FR
München, DE
Athens, GR
Milano, IT
Utrecht, NL
Zug, CH
see more
Locations
Plano, US HQ
Irving, US
Plano, US
Locations
Pasadena, US HQ
Madison, US
San Diego, US
Employees
Employees
7577% decrease
Employees
27028% increase
Employees
74021% increase
Employees
1,2134% increase
Employees
22079% increase
Employees
13416% increase
Valuation ($)
Valuation ($)
3.7 b
Valuation ($)
9.6 b
Valuation ($)
5.4 b
Valuation ($)
818.9 m
Valuation ($)
3.2 b
Valuation ($)
7.9 b
Twitter followers
Twitter followers
3.7 k
Twitter followers
9.1 k
Twitter followers
N/A
Twitter followers
9.8 k
Twitter followers
1.2 k
Twitter followers
2.9 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
21
Number of tweets (last 30 days)
11
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
19
Number of tweets (last 30 days)
30
Number of tweets (last 30 days)
20
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
5.3
Average likes per tweet (last 30 days)
13.4
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
5.3
Average likes per tweet (last 30 days)
4.7
Average likes per tweet (last 30 days)
32.2
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
90.91%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
84.21%
Percentage of tweets with engagement (last 30 days)
90%
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
280538
Alexa Website Rank
313292
Alexa Website Rank
260258
Alexa Website Rank
183640
Alexa Website Rank
N/A
Alexa Website Rank
N/A
Employee Rating
Employee Rating
3.8
Employee Rating
4.1
Employee Rating
4.4
Employee Rating
3.5
Employee Rating
3.8
Employee Rating
4.1

Financial

Revenue (est.)
Revenue (est.)
$729.3m (FY, 2020)
Revenue (est.)
$58m (FY, 2020)
Revenue (est.)
$271m (FY, 2020)
Revenue (est.)
$250.7m (FY, 2020)
Revenue (est.)
$9m (FY, 2020)
Revenue (est.)
$168.8m (FY, 2019)
Cost of goods
Cost of goods
$11.9m (FY, 2020)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$5.4m (FY, 2020)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$717.3m (FY, 2020)
Gross profit
$58m (FY, 2020)
Gross profit
N/A
Gross profit
$245.3m (FY, 2020)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($486.8m) (FY, 2020)
Net income
($134.2m) (FY, 2020)
Net income
($186.6m) (FY, 2020)
Net income
($618.7m) (FY, 2020)
Net income
($247.8m) (FY, 2020)
Net income
$68m (FY, 2019)

Operating

Patents Issued
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
240 (FY, 2016)
Patents Issued
359 (FY, 2016)
Phase I Trials Products
Phase I Trials Products
6 (FY, 2020)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
24 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
6 (FY, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 200.1m
Total funding raised
$ 409m
Total funding raised
$ 468.9m
Total funding raised
$ 147.1m
For sources of this data, please see the company profile

View company profiles

Intellia Therapeutics
HQ
Cambridge, US
Employees
270↑ 28% increase

Intellia is developing therapeutic products to help people with genetic diseases.

View company
Ultragenyx Pharmaceutical
HQ
Novato, US
Employees
740↑ 21% increase

Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.

View company
Bluebird Bio
HQ
Cambridge, US
Employees
1,213↑ 4% increase

Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer.

View company
Reata Pharmaceuticals
HQ
Plano, US
Employees
220

Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.

View company